Peregrine Pharma (PPHM) Misses Q3 EPS by 1c

Peregrine Pharma (NASDAQ: PPHM) reported Q3 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $6.71 million versus the consensus estimate of $7.96 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand